SUPIMA
6.10.2020 15:02:14 CEST | Business Wire | Press release
Supima presents the 3rd annual Supima Design Lab in its very first all-digital format, which will take place on Thursday, October 8th and be streamed live on Supima’s Instagram along with Fashion Network. Once again Supima brings together a select group of up and coming and leading designers from around the world. This year’s Supima Design Lab will showcase exclusive collections designed using American-grown Supima cotton featuring designs by the winner and finalists of the 2020 Supima Design Competition, the selection of the 2020 Hyères Fashion & Photography Festival and by leading International designers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005256/en/
Created exclusively for the Supima Design Lab, each design showcases the endless possibilities of fabrics made with Supima cotton. Stemming from a commitment to design, sustainable innovation and superior quality, Supima is unwavering in its ongoing programs that create platforms for designers to express themselves despite the challenges of Covid-19.
This Year’s Digital Runway show will be presenting “Made with Supima” Exclusive Designs by;
The Winner and Finalists of the 13th Annual Supima Design Competition
Amanda Forastieri, Drexel University – This Year’s Winner
Sakura Mizutani , Fashion Institute of Design & Merchandising
Jenny Feng , Fashion Institute of Technology
Jennie Nguyen , Kent State University
Terrence Zhou , Parsons School of Design
Kyra Buenviaje , Rhode Island School of Design
Finalists of 35th International Festival of Fashion, Fashion Photography and Accessories of Hyères
Katarzyna Agnieszka (France) Andrea Grossi (Italy)
Aline Boubert (France) Marvin M’Toumo (France)
Xavier Brisoux (France) Maximilian Rittler (Belgium)
Emma Bruschi (France) Céline Shen (France)
Timour Desdemoustier (Belgium) Tom van der Borght (Belgium)
Selected Leading Designers
Thierry Colson
Lutz Huelle
Dice Kayek
Jean Paul Knott
On Aura Tout Vu
As a special addition to this year’s Supima Design Lab, there will be a round table orchestrated by Benjamin Simmenauer, Permanent Professor at Institut Français de la Mode, Fashion Expert & Brand Strategist. The round table includes a select panel of industry leaders for an in-depth discussion of the Supima Design Lab - From the Fields to the Runway. This year’s panelists include :
Jean-Pierre Blanc , Founder, International Festival of Fashion, Photography and Accessories of Hyères
Godfrey Deeny , International Editor-in-Chief, FashionNetwork
Marc Lewkowitz , President & CEO, Supima
Buxton Midyette , VP Marketing & Promotions, Supima
« We are truly honored to continue working with our SDC Partner School finalists, the selection from the Festival de Hyères and our Leading Designer group. During the pandemic, we knew it was more important than ever to stay nimble and shift the Supima Design Lab into a virtual format to support these emerging designers achieve success in the fashion industry »
Buxton Midyette, VP Marketing & Promotions, Supima
About Supima :
Supima is America’s premium cotton. Founded in 1954, the Supima brand, short for « Superior Pima », designates an elite variety of pima cotton sustainably grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color and indulgent softness.
Follow Us on Social:
Instagram: @Supima
Facebook: @Supima
Twitter: @Supima
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005256/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom